Delivery Order SPE2DB20D1109-SPE2DB25FP59U
- Not listed
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency (DLA) awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 11, 2025. This non-set-aside contract was competitively awarded on July 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a specialty biologic medication used in the treatment of moderate-to-severe asthma, reflecting DLA's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency (DLA) awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with an ultimate completion date of August 26, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for the supply of TEZSPIRE 210 MG/1.91 ML pen injectors, with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on August 4, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a task under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitively awarded delivery order under the company's existing indefinite delivery contract with DLA. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of TEZSPIRE 210 mg/1.91 ml auto-injector pens valued at $4,687.18. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contract requires completion by September 3, 2025, with performance taking place at AmerisourceBergen's...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP59UDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors, with a ceiling value of $4,687.18. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025. The award utilized competitive procedures with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the federal government's medical supply needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. TEZSPIRE is a biologic medication used in the treatment of asthma, reflecting the contractor's ongoing role as a critical supplier of specialized pharmaceutical commodities to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/18/25 |